Globus Medical (GMED) Announces First Case In Orthopedic Trauma

Posted On September 15, 2017 By OrthoSpineNews In Extremities /

9/15/2017

AUDUBON, Pa., Sept. 14, 2017 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced it completed its first orthopedic trauma surgical case. Globus Medical’s new ANTHEM™ Distal Radius Fracture System was used by Dr. Asif Ilyas, Hand Surgeon and Trauma Surgeon with The Rothman Institute at Thomas Jefferson University in Philadelphia PA, to successfully treat a distal radius fracture.

The ANTHEM™ Distal Radius Fracture System is a comprehensive fixation system designed to treat a variety of traumatic wrist fractures with anatomically contoured plates for intraoperative versatility. “This is the first orthopedic trauma surgery performed using a plating system designed, manufactured and sold by Globus Medical,” said Barclay Davis, Vice President, Orthopedic Trauma. “We are very proud to continue Globus’ reputation for innovation, speed to market, and listening to our surgeon customers, by bringing this philosophy to the orthopedic trauma market. This introduction is the culmination of a significant effort between Globus Medical’s outstanding product development team and leading orthopedic trauma surgeons. And there are many more to come.”

The innovative ANTHEM™ plate design allows a clear view of the fracture line for improved diagnosis and care. “This plate features a positioning slot and screw that allows multidirectional fine tuning of plate position to provide surgeons maximum flexibility during surgery. I am impressed by how intuitive the tray and system are and how natural the instrumentation feels. The implant was seamless in its placement and fixation,” said Dr. Asif Ilyas. “Trauma is a large, busy, and complex space. That space is ready for a company like Globus to take our current designs and technology and advance them to the next level.”

Globus Medical is planning to introduce its new orthopedic trauma product line at the Orthopaedic Trauma Association’s 33rd Annual Meeting to be held October 11-14, 2017 in Vancouver, Canada.

Indications
The ANTHEM™ Fracture System is indicated for fixation of fractures, osteotomies, arthrodesis and reconstruction of bones for the appropriate size of the device to be used in adult patients, including the clavicle, scapula, humerus, radius, ulna, small bones (metacarpals, metatarsals, phalanges), wrist, pelvis, femur, tibia, fibula, ankle, and foot. Small fragment and distal fibula plates may be used in all pediatric subgroups (except neonates) and small stature adults. Distal radius plates may be used in adolescents (12-21 years of age).

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to successfully integrate the international operations acquired from Alphatec, both in general and on our anticipated timeline, our ability to transition Alphatec’s international customers to Globus Medical products, our ability to realize the expected benefits to our results from the Alphatec acquisition, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact :
Daniel Scavilla
Senior Vice President, Chief Financial Officer
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com

Lima Corporate Announces 100,000 SMR Shoulder Prosthesis Implanted Worldwide

Posted On September 15, 2017 By OrthoSpineNews In Extremities, Top Stories /

San Daniele del Friuli, Udine, Italy – 14th September 2017 – Lima Corporate is pleased to announce that, in August, the SMR System reached the significant milestone of 100,000 shoulder prosthesis implanted worldwide. The SMR System is the first shoulder platform launched on the market in 2002, and it has since then encountered a huge success which has led to this important milestone.

The SMR has proven to be an effective and reliable shoulder implant appreciated by surgeons all over the world, thanks to the advantages provided by a modular solution. Together with the celebration of the 15th anniversary of the SMR System on the market and by launching the SMR Bone Graft Instruments and Lima Personalized Surgical Instruments (LPSI), Lima is positioned as the pioneer in modularity applied to shoulder replacement. The innovation and the versatility of the system are now complemented by the SMR Bone Graft Instruments and LPSI Shoulder guides combined with the preoperative planning software.

The SMR Modular Shoulder System is on the market since 2002 and has been developed with the support of several shoulder surgeons, led by Prof. Mario Randelli, from Humanitas Clinical Institute in Milan (Italy). The aim of the SMR System is to provide to surgeons a complete platform, where the modularity of the system allows intraoperative versatility and a simple conversion from anatomic to reverse, without removing the humeral stem and the Metal Back glenoid.

“SMR is the original shoulder modular platform system which is surgeon user-friendly and covers all options in shoulder arthroplasty, backed by excellent clinical results” said Mr. Peter Poon from North Shore Hospital in Auckland (New Zealand).

“I’ve been involved in the development of the SMR and I followed the evolution of the platform over the years, including the use of Trabecular Titanium for glenoid reconstruction. I strongly believe in the modular platform and the cementless use of the implant. I’ve been using the SMR since 2002 in over 600 patients with great clinical results” said Prof. Raffaele Russo from the Pellegrini Hospital in Naples (Italy).

“I started using the SMR as an alternative to the all poly cemented glenoid considering the excellent results published regarding the system. I have continued to use the SMR and subsequently, the Metal Back TT for the past five years because of the system’s versatility and ability it affords me to perform glenoid reconstructions I could not do with any other system”, said Dr. Kevin Setter from SUNY Upstate Medical University, Syracuse (US).

Luigi Ferrari, CEO of Lima Corporate, said about the milestone: “SMR System has been an important component of our growth since its launch on the market in 2002, and today we are proud to celebrate this milestone. SMR is the first shoulder platform with 15 years of clinical follow-up. We see growing excitement for it as we continue to develop innovative solutions to support our surgeon customers in their practice.”

About Lima Corporate Lima Corporate is a global medical device company providing reconstructive orthopaedic solutions to surgeons who face the challenges of improving the quality of life of their patients. Based in Italy, Lima Corporate is committed to the development of innovative products and procedures to enable surgeons to select ideal solution for every individual patient. Lima Corporate’s product range includes large joint revision and primary implants and complete extremities solutions including fixation. For additional information on the Company, please visit: www.limacorporate.com

Limacorporate S.p.a.

Nadine MAO-DESIO

Corporate Marketing & Communication Manager

Via Nazionale, 52

3038 Villanova di San Daniele

Udine – Italy

T: +39 0432 945511

E: nadine.maodesio@limacorporate.com

Proven 10-year Excellence in HemiCAP® Joint Replacement for Hallux Rigidus

Posted On September 12, 2017 By OrthoSpineNews In Extremities, Top Stories /

FRANKLIN, Mass., Sept. 12, 2017 /PRNewswire/ — Arthrosurface, Inc. announced today the publication of long-term HemiCAP® data in The Journal of Foot and Ankle Surgery, “10 Year Follow-Up of Metatarsal Head Resurfacing Implants for Treatment of Hallux Rigidus.” The study reported excellent pain relief, functional improvement, high patient satisfaction, a low reoperation rate and no serious complications.

Hallux Rigidus describes a painful condition which affects the big toe at the first metatarsal joint. Osteophytes, or bone spurs, develop on the dorsal surface of the bones involved, which limit motion and cause pain. Advanced disease may also include degenerate cartilage on the joint surfaces, which can contribute to patient pain.

Historically, arthrodesis, or joint fusion, was the standard of care to address patients’ symptoms in advanced stages, however, with eliminated joint motion, patients have shown difficulties with rising on their toes, kneeling or taking a full stride when walking. Other complications include non-union of the fusion site in about 10% of the procedures.

The proprietary HemiCAP® Implant System is designed to maximize implant stability through a strong threaded fixation component and optimizes the fit with a range of implant curvatures. As an active alternative to joint fusion, the HemiCAP® System allows physicians to provide patient specific solutions with hemiarthroplasty of the first and lesser toes, as well as total joint replacement of the big toe. The motion preserving platform provides a complete solution for primary and revision surgery, while maintaining an exit into joint fusion. To date more than 33,000 implants have been used.

“Patients today want to maintain their toe mobility to stay active, whether it is playing golf, performing yoga or being able to continue to live independently,” said Lisa Donnelly VP of Marketing. “We see tremendous traffic on our website from patients inquiring how to find a physician who is trained on our technologies. We have recently launched a new physician locator covering a nationwide network of approximately 1,000 foot and ankle surgeons to help assist them.”

“It is very satisfying to see the AOFAS score of 90.6 at the 10-year follow-up and the high degree of patient satisfaction,” said Steve Ek, President & CEO of Arthrosurface. “We hope this data continues to drive the clinical and patient communities to question the role of motion sacrificing procedures in the first MTP joint, as has happened over time in multiple other joints”.

About Arthrosurface

Arthrosurface, Inc. is a global orthopedic medical technology business providing a broad portfolio of essential products and instrumentation used to treat upper and lower extremity orthopedic conditions caused by trauma, injury and arthritic disease. The product offerings include devices, instruments and orthobiologics designed to preserve and restore the joints so patients can regain and maintain an active lifestyle. The Company offers a variety of unique systems that provide less invasive technologies for surgeons that can be used to treat a wide range of joint conditions. Founded in 2002, Arthrosurface markets and distributes its products in the US and around the world and has succeeded in helping patients return to activity for over 13 years. For more information, please go to our website at www.arthrosurface.com

SOURCE Arthrosurface, Inc.

Centric Medical™ Achieves Record Sales Growth of Foot and Ankle and Biologics Product Lines over Past Year

Posted On September 7, 2017 By OrthoSpineNews In Extremities /

September 05, 2017

HUNTLEY, Ill.–(BUSINESS WIRE)–Centric Medical, a division of Life Spine^®, Inc., which focuses on developing surgical implants for the treatment of lower distal extremity pathology, announced today record revenue growth of their TARSA-LINK^™ Stand-Alone Wedge Fixation System and ROGUE^™ Hammertoe Correction System within their Foot & Ankle division, plus OSTEO-LINK^® 100% Demineralized Bone Matrix and MARROW CELLUTION^™ Bone Marrow Harvesting System within their Biologics division.

“The groundbreaking TARSA-LINK Stand-Alone Wedge Fixation System, which was the market’s first stand-alone osteotomy wedge with built-in fixation, along with the TARSA-LINK Bunion Correction System designed as the first stand-alone opening base wedge with built-in fixation on the market, have provided us with a leading foot and ankle portfolio offering,” said Mariusz Knap, Vice President of Marketing and Business Development for Life Spine. “We then introduced the ROGUE Hammertoe Correction System to the market, amongst other products. The revenue gained within Centric Medical in the past eight months alone is over 112% compared to the full year prior. These innovative systems are just a small part of a successfully growing foot and ankle portfolio.”

“Within the Osteobiologics product division, revenue growth of 105% has already been seen in the past eight months when compared to the prior full year,” continued Mr. Knap. According to in-vivo test results, OSTEO-LINK has been engineered and processed to deliver the highest level of osteoinductivity characteristic with 100% DBM by weight. “We are excited to include our new offering called OSTEO-LINK Hydratable ICM (Inductive Carrier Matrix), which is an osteoinductive bone matrix that may be hydrated with saline, blood, BMA, or PRP. We can also offer surgeons the ability to capture BMA with our MARROW CELLUTION Bone Marrow Harvesting System. It is designed to overcome the limitations of a traditional bone marrow needle and results in a bone marrow harvest that is so rich in key stem and progenitor cells that the aspirate may no longer require manipulation through centrifugation prior to application. This allows the surgeon to complete a true bone healing triad for the greatest possible clinical outcomes.”

About Centric Medical

Centric Medical is dedicated to improving the quality of life for patients with distal extremity symptomatology, increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Centric Medical, which is privately held, is based in Huntley, Illinois. For more information, please visit: http://www.centricmedical.com.

Contacts

Centric Medical
Mr. Omar Faruqi
Chief Financial Officer
ofaruqi@lifespine.com
847-884-6117

Halyard Health Introduces Five New COOLIEF* Multi-Cooled RF Kits

Posted On September 7, 2017 By OrthoSpineNews In Extremities, Top Stories /

ALPHARETTA, Ga., Sept. 6, 2017 /PRNewswire/ — Halyard Health (NYSE: HYH), a medical technology company focused on eliminating pain, speeding recovery and preventing infection, today announced the introduction of five new COOLIEF* Multi-Cooled RF Kits for use in performing COOLIEF Cooled Radiofrequency (RF) treatments. The new kits expand upon the four existing COOLIEF Multi-Cooled RF Kits by offering different component lengths and active tip sizes to treat additional modalities with our multi-probe kits. These kits allow physicians to ablate up to three nerves at once, saving time and the inconvenience of having to open multiple kits and components.

The new COOLIEF Multi-Cooled RF Kits have been developed to target nerves within the spine and knee. Each kit is equipped with all the components necessary to conduct a multi-probe COOLIEF Cooled RF treatment including the new COOLIEF* Fluid Delivery Introducer (FDI). The FDI enables fluids to be instilled through the port so that the physician can maintain probe placement and reduce instances of repositioning. The five new configurations of COOLIEF Multi-Cooled RF Kits include:

MCK2-17-50-2 (Cervical): 2 Probes, 4 Introducers, 2 Tube Kits
MCK2-17-50-4 (Knee): 2 Probes, 4 Introducers, 2 Tube Kits
MCK2-17-75-2 (Cervical): 2 Probes, 4 Introducers, 2 Tube Kits
MCK2-17-75-5.5 (Thoracic): 2 Probes, 4 Introducers, 2 Tube Kits
MCK3-17-50-4 (Knee): 3 Probes, 6 Introducers, 2 Tube Kits

“The addition of these five new multi-probe kits more than doubles the number of COOLIEF Multi-Cooled RF Kits available to pain physicians,” said Phil Cranmer, associate marketing director, Interventional Pain Management, Halyard Health. “Rather than having to piece together multiple kits and components, the COOLIEF Multi-Cooled RF Kit provides everything they need to perform multiple lesions simultaneously in one cost-effective package based on the type of procedure required.”

COOLIEF Cooled RF is the first and only treatment to receive clearance from the U.S. Food and Drug Administration (FDA) for the relief of chronic moderate to severe knee pain caused by osteoarthritis (OA). COOLIEF Cooled RF is a minimally-invasive and non-surgical outpatient procedure to target and treat the nerves causing chronic pain. This advanced thermal radiofrequency pain management system uses water-cooled technology to safely deactivate pain-causing sensory nerves. COOLIEF Cooled RF has been shown to provide up to 24 months of pain relief, improved physical functionality, and reduced drug utilization.

To learn more about COOLIEF Cooled RF, please visit http://www.halyardhealth.com/chronicpain.

About Halyard Health

Halyard Health Inc. (NYSE: HYH) is a medical technology company focused on eliminating pain, speeding recovery and preventing infection for healthcare providers and their patients. Headquartered in Alpharetta, Georgia, Halyard is committed to addressing some of today’s most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery and preventing healthcare-associated infections. Halyard’s business segments – Medical Devices and Surgical and Infection Prevention (S&IP) – develop, manufacture and market clinically superior solutions that improve medical outcomes and business performance in more than 100 countries. For more information, visit www.halyardhealth.com.

*Registered Trademarks or Trademarks of Halyard Health, Inc. or its affiliates.

SOURCE Halyard Health, Inc.

Exactech To Present to Investors at Baird 2017 Global Healthcare Conference

Posted On September 5, 2017 By OrthoSpineNews In Extremities /

September 05, 2017

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, will present to investors at the Baird 2017 Global Healthcare Conference in New York on Thursday, September 7, 2017. The company will also host one-on-one meetings with institutional investors.

The presentation by Exactech CEO David Petty and Executive Vice President of Finance & CFO Jody Phillips will begin at 10:50 a.m. and will be available via webcast at http://wsw.com/webcast/baird49/exac/. The replay will be available for 90 days.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.

An investment profile on Exactech may be found at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

Contacts

Exactech, Inc.
Investor contacts
Jody Phillips, 352-377-1140
Executive Vice President of Finance & Chief Financial Officer
or
Media contact
Priscilla Bennett, 352-377-1140
Vice President, Corporate & Marketing Communication
or
Hawk Associates
Julie Marshall or Frank Hawkins, 305-451-1888
E-mail: EXAC@hawkassociates.com

Seven of Colorado’s Top Private Orthopedic Practices Come Together to Form Orthopedic Centers of Colorado, Now the State’s Largest Practice

Posted On August 31, 2017 By OrthoSpineNews In Extremities, Spine, Sports Medicine, Top Stories /

DENVER, Aug. 31, 2017 /PRNewswire/ — Fifty-six of Colorado’s top orthopedic physicians, across seven practices, have united under a common vision of improving outcomes, efficiency, cost, and quality to form Orthopedic Centers of Colorado, LLC (OCC). With 19 offices across the Denver metro area, the combined practice is the largest provider of orthopedic and musculoskeletal care in the state.

The seven practices coming together as Orthopedic Centers of Colorado, LLC are:

Advanced Orthopedic & Sports Medicine Specialists P.C.
Colorado Orthopedic Consultants, P.C.
Denver Spine Surgeons, LLC
Denver-Vail Orthopedics, P.C.
Hand Surgery Associates, P.C.
Orthopedic Associates, LLC
Peak Orthopedics & Spine, PLLC

In a market where just 33 percent of physicians work in independent practice, down from 48 percent in 2012, this formation represents a physician-driven commitment to the private-practice model of medicine.

“The private-practice model has proven to deliver a higher level of quality at a more competitive price,” said Davis Hurley, MD, president of Orthopedic Centers of Colorado. “Patients will continue to benefit from the more personalized approach that private practice delivers to accommodate each patient’s needs.”

As a physician-driven organization, OCC will remain nimble enough to adapt to the ever-changing healthcare landscape, and emerge as pioneers in improved patient outcomes and reduced costs, while maintaining strong personal relationships with the patients from the communities we serve.

The seven practices will begin operating as Orthopedic Centers of Colorado on September 1, 2017. Patients of the practices will see no interruption in their care and services and will begin to see the OCC name on patient communications.

About Orthopedic Centers of Colorado, LLC
The number one choice for orthopedic, hand and spine health in Colorado and the Rocky Mountains, Orthopedic Centers of Colorado is an independent group of 56 physicians focused on patient specific care, quality outcomes, value and continuous improvement. We’ve assembled the best doctors across nearly 30 areas of expertise including Colorado’s best sports medicine and orthopedic physicians. Patients can visit any of our 19 convenient locations for care from doctors who believe quality patient care starts with a great patient experience. Learn more at orthocentersco.com

SOURCE Orthopedic Centers of Colorado, LLC

Peninsula Orthopaedic Associates Announces First MACI Implant in the Region for the Treatment of Cartilage Defects of the Knee

Posted On August 24, 2017 By OrthoSpineNews In Biologics, Extremities, Top Stories /

SALISBURY, Md., Aug. 24, 2017 /PRNewswire/ — POA, a large regional orthopaedic specialty group, announced their first successful implant of MACI^® (autologous cultured chondrocytes on a porcine collagen membrane) in the region. MACI is an FDA-approved product, in which a patient’s own cartilage cells from the knee are regrown in a laboratory and implanted back into the patient’s knee to repair the defect.

With the introduction of MACI, surgeons now have an FDA approved product in which the patient’s own cells can be reproduced in a controlled lab environment, embedded on a special collagen membrane, and then implanted in the knee using a minimally invasive technique. “Joint preservation surgery has undergone its next evolution. With this new technology, we can use a patient’s own cells to grow new cartilage to preserve their joint. The scaffold which delivers their cells allow for minimally invasive surgery and smaller incisions. We are working on an all-arthroscopic technique, as well. While this operation will not work for an arthritic knee, it has the promise of preserving a knee and potentially preventing future arthritis,” says Orthopaedic Surgeon Dr. Jason Scopp.

About MACI

MACI^® (autologous cultured chondrocytes on a porcine collagen membrane) is an autologous cellular scaffold product that is used in the repair of symptomatic single or multiple full-thickness cartilage defects of the knee, with or without bone involvement in adults. The MACI implant consists of autologous cultured chondrocytes seeded onto a resorbable type I/III collagen membrane. Autologous cultured chondrocytes are human-derived cells which are obtained from a patient’s own cartilage for the manufacturing of MACI. The FDA approval of MACI was supported by the results of SUMMIT trial, a Phase 3 two-year trial.

About POA

Peninsula Orthopaedic Associates is a multi-specialty orthopaedic practice with offices in Berlin and Salisbury, Marylandand Millsboro and Seaford, Delaware. With over 50 years of providing comprehensive orthopaedic care, we provide expertise in foot and ankle, hand, hip and knee, shoulder and elbow, spine, sports medicine, joint replacement, joint preservation, orthopaedic trauma care, performance enhancement and rehabilitation, and biologic solutions, in order to offer an expansive continuum of care for our region.

For more information, please visit the MACI website at maci.com, or contact Jessica Ennis at
410-860-4506 or jennis@peninsulaortho.com.

SOURCE Peninsula Orthopaedic Associates

Fig-4-Stryker-C-system-illustrating-a-bridging-external-fixator-used-for-distal-radius.png

Global Trauma Fixation Devices Market 2017-2021 with Stryker, Zimmer Biomet & Smith & Nephew Dominating – Research and Markets

Posted On August 22, 2017 By OrthoSpineNews In Extremities, Sports Medicine /

August 21, 2017

DUBLIN–(BUSINESS WIRE)–The “Global Trauma Fixation Devices Market 2017-2021” report has been added to Research and Markets’ offering.

The global trauma fixation devices market to grow at a CAGR of 7.29% during the period 2017-2021.

Global Trauma Fixation Devices Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the sales and value of the trauma fixation devices market.

According to the report, one of the major drivers for this market is Sports injuries. Sports injuries are common among athletes. According to the CDC, in 2011, sports-related injuries resulted in 3.2 million visits to the emergency room (ER) for children below the age of 19.

The latest trend gaining momentum in the market is Technological advancements. Due to the growing demand for trauma fixation devices, companies are developing technologically advanced products to improve their market share.

The product is Conformité Européene (CE) approved for sales in the US. Similarly, bioresorbable plates, pins, and screw implants are widely used for fracture fixation in orthopedic surgeries and trauma care. These bioresorbable products dissolve in the human body. Hence, operations to remove the synthetic material are not required. They also do not corrode or accumulate metals in the tissue.

Further, the report states that one of the major factors hindering the growth of this market is Complications associated with trauma fixation devices. Trauma fixation devices can cause several complications. Surgical procedures that use trauma fixation devices can cause neurological or soft tissue damage, which can lead to paralysis. In some cases, bones take longer time to fuse with the implants. Sometimes, they might not even fuse. Such complications could require corrective surgeries.

Key vendors

Stryker
Zimmer Biomet
Smith & Nephew

Other prominent vendors

Auxein Medical
Brace Orthopaedic
CONWELL MEDICAL
Bioretec
Citieffe
Invibio
B. Braun Melsungen
ReWalk Robotics
NuVasive
FirstRay
OMNI
Orthopeadic Implant Company
PAVIS

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market landscape

Part 06: Segmentation by product type

Part 07: Segmentation by end-user

Part 08: Segmentation by geography

Part 09: Drivers and challenges

Part 10: Market trends

Part 11: Vendor landscape

Part 12: Key vendor analysis

Part 13: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/kcpncl/global_trauma

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Orthopedic Devices

DePuy Synthes, Wright Medical Lead US Market for Orthopedic Small Bone and Joint Devices Due to Increased Foot & Ankle Procedures

Posted On August 21, 2017 By OrthoSpineNews In Extremities /

Vancouver, BC — (ReleaseWire) — 08/18/2017 –According to a new series of reports on the U.S. market for orthopedic small bone and joint devices by iData Research (www.idataresearch.com), growth in the market is led by the foot & ankle device and shoulder reconstruction device segments. The fastest growing segment is the foot & ankle market, which grew roughly 9% in 2016. The foot & ankle device market features by far the greatest number of procedures, but many of them use relatively inexpensive implants. There is a trend towards arthroplasty devices over arthrodesis, which carries a higher average selling price (ASP) such as with ankle replacement over fusion and the treatment of hammertoe with implants over K-wires. This shifts in product preference are propelling the foot & ankle market’s growth due to the adoption of devices with higher ASPs.

“As the U.S. small bone and joint orthopedic market is adapting to the needs of the aging population, there is a need for regular updates, revisions, and brand-new products being introduced to the market,” explains Jeffrey Wong, Strategic Analyst Manager at iData Research. “With new innovations, physician training and proficiency in adopting any new product is crucial to its success.”

To see the contents of this orthopedics market report, please visit idataresearch.com.

The quality of device implantation depends on the proficiency of the surgeon and, as a result, the majority of procedures will be limited to centers where a high volume of implants is placed. This limitation will change as designs improve and durability data accumulates, resulting in more physician acceptance. Total wrist replacement remains a small market, but the shift towards the use of ulnar head replacement has already begun. This demonstrates that new products and procedures for the total wrist replacement market is slowly being accepted by more physicians in the region.

DePuy Synthes leads the U.S. small bone and joint orthopedic device market due to their strong market position in both the plate & screw and the external fixation device markets. DePuy Synthes was also very strong in the shoulder reconstruction, staple fixation, and foot & ankle device markets. DePuy Synthes’ largest revenues came from the shoulder reconstruction devices market, followed closely by the plate & screw device market, especially the distal radius plate market. The company was the first to introduce locking plates, which contributed considerably to the internal fixation market because of higher average selling prices per unit.

READ THE REST HERE